For the quarter ending 2025-09-30, LAB had -$29,198K decrease in cash & cash equivalents over the period. -$23,088K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -34,687 | -59,492 |
| Bargain purchase gain | 0 | 0 |
| Stock-based compensation expense | 8,474 | 15,396 |
| Amortization of acquired intangible assets | 0 | 1,715 |
| Depreciation and amortization | 1,521 | 6,450 |
| Accretion of discount on short-term investments, net | 611 | 1,571 |
| Non-cash lease expense | 1,570 | 2,865 |
| Provision for excess and obsolete inventory | 615 | 1,360 |
| Change in fair value of warrants | 0 | -232 |
| Change in fair value of contingent consideration | 0 | -3,400 |
| Other non-cash items | 445 | 477 |
| Accounts receivable, net | 5,794 | 2,297 |
| Inventory | 1,804 | 8,548 |
| Prepaid expenses and other assets | 705 | 1,175 |
| Accounts payable | 946 | 838 |
| Accrued liabilities | 8,774 | 1,485 |
| Deferred revenue | 700 | -1,900 |
| Operating lease liabilities | -1,673 | -3,065 |
| Other liabilities | 27 | 143 |
| Net cash used in operating activities | -22,202 | -50,951 |
| Cash and restricted cash acquired in merger | 0 | 0 |
| Purchases of short-term investments | 40,312 | 50,929 |
| Purchases of long-term investments | 19,483 | - |
| Proceeds from sales and maturities of investments | 54,000 | 100,000 |
| Purchases of property and equipment | 886 | 6,941 |
| Net cash provided by investing activities | -6,681 | 42,130 |
| Repayment of term loan and convertible notes | 0 | 0 |
| Payment of term loan fee | 0 | 0 |
| Repurchase of common stock | 0 | 0 |
| Proceeds from espp stock issuance | 0 | 308 |
| Payments for taxes related to net share settlement of equity awards and other | 112 | 246 |
| Proceeds from exercise of stock options | 0 | 0 |
| Net cash provided by (used in) financing activities | -112 | 62 |
| Effect of foreign exchange rate fluctuations on cash and cash equivalents | -203 | 1,145 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -29,198 | -7,614 |
| Cash and cash equivalents at beginning of period | 168,818 | - |
| Cash and cash equivalents at end of period | 132,006 | - |
STANDARD BIOTOOLS INC. (LAB)
STANDARD BIOTOOLS INC. (LAB)